• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Rodriguez Patrick

    1/22/26 4:15:20 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Rodriguez Patrick

    (Last) (First) (Middle)
    300 FRANK W. BURR BLVD., STE 21

    (Street)
    TEANECK NJ 07666

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/12/2026
    3. Issuer Name and Ticker or Trading Symbol
    PHIBRO ANIMAL HEALTH CORP [ PAHC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP Finance and Treasurer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List - Exhibit 24.1 Power of Attorney
    No securities are beneficially owned.
    /s/ Judith Weinstein, as Attorney-in-Fact for Patrick Rodriguez 01/22/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PAHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAHC

    DatePrice TargetRatingAnalyst
    7/7/2025$35.00Neutral → Overweight
    Analyst
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    9/10/2024$22.00Neutral
    JP Morgan
    12/7/2023$9.00Underperform
    Exane BNP Paribas
    12/21/2022$18.00Buy
    ROTH Capital
    7/25/2022$22.00Equal Weight → Underweight
    Barclays
    1/10/2022$23.00Underweight → Equal-Weight
    Barclays
    11/18/2021$23.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PAHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bendheim Jack converted options into 185,000 shares and sold $5,362,103 worth of shares (110,842 units at $48.38) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/9/26 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack converted options into 30,000 shares and sold $545,473 worth of shares (13,180 units at $41.39) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/5/26 7:22:29 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $540,037 worth of shares (13,465 units at $40.11) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/2/26 4:15:18 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    SEC Filings

    View All

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    2/4/26 4:41:36 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Phibro Animal Health Corporation

    10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    2/4/26 4:16:16 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    2/3/26 4:20:35 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024): Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Diluted earnings per share of $0.67, an increase of $0.59 Adjusted EBITDA of $68.1 million, an increase of $19.9 million, or 41% Adjusted net income of $35.7 million, an increase of $13.5 million, or 60% Adjusted dil

    2/4/26 4:25:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 25, 2026, to stockholders of record at the close of business on March 4, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www

    2/3/26 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To

    1/28/26 4:30:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phibro Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00

    7/7/25 8:10:48 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00

    6/16/25 8:16:19 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Phibro Animal Health with a new price target

    JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00

    9/10/24 7:55:45 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces Leadership Transition

    Jack Bendheim to Assume the Role of Executive Chairman; Daniel Bendheim Named Chief Executive Officer and President Phibro Animal Health Corporation (NASDAQ:PAHC) (the "Company" or "Phibro") today announced a leadership transition that will support the Company's continued growth and long-term strategic direction. At the end of this fiscal year, effective July 1, 2026, Jack Bendheim, current Chairman, Chief Executive Officer and President of Phibro will take on a new managerial role as Executive Chairman and Daniel (Dani) Bendheim will assume the role of Chief Executive Officer and President of Phibro. Jack Bendheim will continue to serve as the Chairman of the Board of Directors of the Com

    12/18/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    1/23/25 4:45:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    9/6/23 12:20:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Financials

    Live finance-specific insights

    View All

    Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024): Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Diluted earnings per share of $0.67, an increase of $0.59 Adjusted EBITDA of $68.1 million, an increase of $19.9 million, or 41% Adjusted net income of $35.7 million, an increase of $13.5 million, or 60% Adjusted dil

    2/4/26 4:25:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 25, 2026, to stockholders of record at the close of business on March 4, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www

    2/3/26 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To

    1/28/26 4:30:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care